12.1 Gastrointestinal Decontamination: Activated Charcoal, Whole Bowel Irrigation, and Contraindications

Gastrointestinal (GI) decontamination encompasses clinical techniques designed to reduce the systemic bioavailability of ingested xenobiotics by physically removing them from the digestive tract or binding them intraluminally before absorption occurs. Historically applied indiscriminately to nearly all acute overdoses, modern toxicology has shifted toward a highly selective, evidence-based approach. The decision to undertake GI decontamination requires the Specialist in Poison Information (CSPI) and bedside clinician to balance the anticipated clinical severity of the exposure against the procedural risks, physiological contraindications, and elapsed time since ingestion.

---

Single-Dose Activated Charcoal (SDAC)

Activated charcoal is a fine, odorless, black, tasteless powder produced by the pyrolysis of carbonaceous materials (such as wood, peat, coconut shells, or petroleum) followed by chemical or thermal activation at high temperatures (600°C to 900°C) with steam or carbon dioxide. This process creates an immense internal pore network, generating a surface area of 950 to 2,000 m² per gram.

Mechanism of Adsorption:
Xenobiotic in Gut Lumen  +  Activated Charcoal Pores
                     │
                     ▼
Non-Covalent Adsorption (Van der Waals Forces, Hydrogen Bonding, Electrostatic Interactions)
                     │
                     ▼
Stable Toxin-Charcoal Complex Excreted in Feces (Prevents Enterocyte Diffusion)

1. Mechanism and Pharmacokinetics of Adsorption

Activated charcoal adsorbs xenobiotics onto its vast porous surface through weak, non-covalent interactions, predominantly van der Waals forces, hydrogen bonding, and dipole-dipole interactions. Because binding is an equilibrium process, adsorption occurs most effectively when the xenobiotic is in a non-ionized, non-polar state, and when a high charcoal-to-toxin mass ratio (typically 10:1) is established within the gastrointestinal lumen.

2. The One-Hour Clinical Window and Kinetic Exceptions

Robust clinical evidence and joint position statements by the American Academy of Clinical Toxicology (AACT) and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) demonstrate that the clinical efficacy of SDAC declines precipitously as time elapses post-ingestion:

• Within 30 minutes: Reduces drug absorption by up to 47% to 70%.
• At 60 minutes: Reduces drug absorption by approximately 30% to 40%.
• Beyond 120 minutes: Overall systemic absorption reduction drops to less than 15% to 20%, which rarely alters patient clinical outcomes.

Elapsed Time Post-Ingestion vs. Fractional Bioavailability Reduction:
[0 to 30 min]   =========> ~50% - 70% Reduction (Optimal Efficacy Window)
[30 to 60 min]  ====>      ~30% - 40% Reduction (Standard Clinical Threshold)
[> 60 to 120m]  ==>        ~15% - 20% Reduction (Marginal Clinical Benefit)
[> 120 min]     >          < 10% - 15% Reduction (Generally Ineffective)

Justified Exceptions to the One-Hour Rule

While routine administration past 1 hour is not recommended, the CSPI should advise extending the administration window up to 2 to 4 hours (or occasionally longer) in specific clinical scenarios:

1. Ingestion of Sustained-Release (SR) or Extended-Release (ER/XR/XL) Formulations: Continuous delayed dissolution in the distal stomach and small bowel allows charcoal to intercept unreleased drug long after ingestion.
2. Agents That Delay Gastric Emptying: Xenobiotics with prominent anticholinergic properties (antihistamines, tricyclic antidepressants, belladonna alkaloids) or opioid receptor agonism produce marked gastroparesis and pyloric sphincter spasm, retaining drug tablets in the stomach for many hours.
3. Massive Overdoses Forming Pharmacobezoars: Large ingestions of poorly soluble tablets (salicylates, carbamazepine, meprobamate) frequently form dense, concrete-like agglutinations (bezoars) in the gastric fundus with prolonged dissolution kinetics.
4. Ingestion of Life-Threatening Toxins Lacking Antidotes: Colchicine, amatoxin mushrooms, and paraquat carry catastrophic mortality, justifying administration beyond 1 hour if any possibility of unabsorbed toxin persists.

3. Dosing and Administration Protocols

• Standard Weight-Based Dosing: 1 g/kg of body weight administered orally or via nasogastric/orogastric tube.
• Adults and Adolescents: 50 to 100 g as an initial single dose.
• Infants and Young Children (under 12 years): 25 to 50 g (or 1 g/kg). For neonates and infants under 1 year, 0.5 to 1 g/kg.
• Preparation: Administered as an aqueous slurry (typically 20% to 25% suspension in water). Flavored formulations with sorbitol or flavoring agents may improve palatability in conscious patients.

4. Absolute and Relative Contraindications

Administering activated charcoal to an inappropriate patient can result in devastating iatrogenic morbidity. The CSPI must strictly enforce the following contraindications:

• Unprotected Airway and Depressed Sensorium: Patients with somnolence, stupor, delirium, or an absent gag reflex must never receive activated charcoal while non-intubated. Emesis with pulmonary aspiration of charcoal leads to intractable chemical pneumonitis, mechanical airway plugging, bronchiolitis obliterans, and severe respiratory failure.
• Gastrointestinal Perforation or Mechanical Bowel Obstruction: Charcoal extravasating into the peritoneal cavity causes dense, fibrous foreign-body peritonitis and irreversible adhesive intestinal obstruction.
• Caustic or Corrosive Ingestions (Strong Acids and Alkalis): Charcoal does not bind caustics, induces vomiting that re-exposes the esophagus and airway to corrosive injury, and coats the gastrointestinal mucosa in black pigment, severely obscuring subsequent diagnostic fiberoptic endoscopy.
• Hydrocarbon Ingestions (Volatile Solvents and Fuels): Hydrocarbons have low surface tension and low viscosity. Charcoal does not bind hydrocarbons, and the emesis it provokes drastically escalates the risk of pulmonary aspiration and fatal chemical pneumonitis.

5. Substances Not Bound by Charcoal: The PHAILS Mnemonic

Certain xenobiotics possess molecular properties that render them refractory to adsorption by activated charcoal. These molecules are typically small, highly polar, charged, ionic, or inorganic species that lack the lipophilicity or carbon-lattice structure necessary to establish van der Waals or dipole interactions within charcoal pores.

PHAILS Mnemonic for Charcoal Inefficacy:
P - Pesticides (organophosphates, carbamates, paraquat - bind poorly in practice) / Potassium
H - Hydrocarbons (petroleum distillates, kerosene, gasoline, mineral spirits)
A - Acids and Alkalis (caustic corrosives: sulfuric acid, sodium hydroxide, bleach)
I - Iron (and other heavy metals: lead, mercury, arsenic, zinc)
L - Lithium (small, univalent alkali metal cation)
S - Solvents and Alcohols (ethanol, methanol, ethylene glycol, isopropanol, acetone)

---

Whole Bowel Irrigation (WBI)

Whole bowel irrigation is an active gastrointestinal decontamination procedure designed to mechanically flush out unabsorbed intestinal contents by administering massive volumes of an osmotically balanced polyethylene glycol electrolyte lavage solution (PEG-ELS).

1. Pharmacological Properties of PEG-ELS

Standard solutions (such as GoLYTELY or CoLyte) utilize high-molecular-weight polyethylene glycol (PEG 3350) combined with physiological concentrations of sodium chloride, sodium bicarbonate, and potassium chloride. The solution is iso-osmolar with human plasma:

• It creates zero net fluid absorption or secretion across the enterocyte brush border.
• It produces no net shifts in serum sodium, potassium, or chloride, even when infused in massive quantities (10 to 20 liters).
• It acts purely by mechanical volume displacement, inducing rapid liquid transit and continuous rectal purging.

2. Clinical Indications for WBI

WBI is reserved for three major high-morbidity toxicological presentations:

1. Body Packers and Body Stuffers: Individuals who have ingested packaged, illicit packets (condoms, latex balloons, plastic wrap) of cocaine, heroin, or methamphetamine. WBI accelerates packet transit while avoiding surgical enterotomy, provided the packets remain intact.
2. Large Ingestions of Sustained-Release or Enteric-Coated Medications: Sustained-release calcium channel blockers (verapamil SR, diltiazem CD/ER), beta-adrenergic antagonists, and theophylline that continue to release toxic drug burdens over 24 to 48 hours.
3. Heavy Metal Ingestions with Radiopaque Tablets: Iron, lead-containing objects or paint chips, and zinc, which are not adsorbed by activated charcoal and can be followed on serial abdominal radiographs; sustained-release lithium is another charcoal-resistant WBI candidate, although lithium tablets are not reliably radiopaque.

WBI Clinical Decision Workflow:
Candidate Patient Identified
       │
       ├─► Check Contraindications: Bowel obstruction? Ileus? Perforation? Unprotected airway?
       │         │
       │         └─► YES ──► ABORT WBI (Risk of fatal aspiration or perforation)
       │
       └─► NO ──► Place Nasogastric Tube + Infuse PEG-ELS
                   │
                   ▼
           Monitor Rectal Effluent & Serial Abdominal Radiographs
                   │
                   ▼
           Continue Until Effluent Is Completely Clear & Radiographs Show No Residual Pills

3. Administration Protocol and Flow Rates

WBI requires high flow rates that are virtually impossible for an ill, nauseated patient to consume voluntarily; therefore, administration via a flexible nasogastric tube using an enteral infusion pump is standard practice.

Antiemetic Pre-Treatment and Procedural Endpoints

• Antiemetic Administration: High-rate gastric distension frequently triggers emesis. Pre-treating the patient with intravenous ondansetron (4 to 8 mg IV) or metoclopramide minimizes nausea and preserves gastric emptying.
• Endpoint Criteria: WBI is continued until rectal effluent runs completely clear (translucent with no suspended fecal particulate matter or pill debris) AND post-procedure abdominal radiographs (for radiopaque agents like iron or body packets) confirm complete gastrointestinal clearance.

4. Contraindications to Whole Bowel Irrigation

• Gastrointestinal Bowel Obstruction or Paralytic Ileus: Administering liters of non-absorbable solution against a blocked or non-motile bowel leads to massive proximal bowel distension, ischemic necrosis, and catastrophic perforation.
• Gastrointestinal Perforation or Hemorrhage: Absolute contraindication.
• Unprotected Airway: Similar to activated charcoal, an obtunded patient undergoing WBI without an endotracheal tube faces high risks of pulmonary aspiration and asphyxiation from massive volumes of PEG-ELS.
• Hemodynamic Shock or Intractable Vomiting: Severe circulatory instability impairs mesenteric perfusion, increasing the risk of non-occlusive mesenteric ischemia during fluid loading.

---

Obsolete and Harmful Decontamination Modalities

Clinical toxicology has definitively rejected several historical decontamination procedures following extensive research demonstrating an absence of clinical benefit and high rates of procedural morbidity.

1. Syrup of Ipecac: Complete Abandonment

Derived from the dried rhizome and roots of Carapichea ipecacuanha, syrup of ipecac contains the active alkaloids emetine and cephaeline, which induce vomiting through direct local irritation of the gastric mucosa and stimulation of the central chemoreceptor trigger zone (CTZ) in the area postrema.

• Reasons for Abandonment:
  1. Failure to Alter Clinical Outcomes: Studies consistently demonstrated that ipecac-induced emesis removes an unpredictable and clinically insignificant fraction of ingested drug (less than 30% even within 15 minutes).
  2. Prolonged Intractable Emesis: Vomiting frequently persists for 1 to 2 hours, preventing the administration of life-saving activated charcoal, oral antidotes (e.g., oral N-acetylcysteine), or whole bowel irrigation.
  3. High Morbidity: Severe complications include Mallory-Weiss gastroesophageal lacerations, spontaneous pneumomediastinum/Boerhaave syndrome, and fatal pulmonary aspiration.
  4. Chronic Abuse Cardiotoxicity: Individuals with eating disorders (anorexia nervosa, bulimia) who chronically ingest ipecac accumulate emetine in cardiac myocytes, resulting in lethal toxic cardiomyopathy, congestive heart failure, and ventricular dysrhythmias.
• Official Guidance: The AACT and EAPCCT issued definitive position statements concluding that syrup of ipecac should not be administered under any circumstances in healthcare facilities or the home, and all bottles should be discarded from residential medicine cabinets.

2. Gastric Lavage ('Stomach Pumping')

Gastric lavage involves inserting a large-bore orogastric tube (36 to 40 French in adults, 22 to 24 French in children) into the stomach, followed by sequential instillation and manual aspiration of small aliquots (200 to 300 mL) of lukewarm normal saline or tap water.

• Reasons for Obsolescence:
  • Severe Procedural Hazards: Even when performed by experienced operators, gastric lavage carries high risks of esophageal perforation, gastric mucosal avulsion, tension pneumothorax, hypoxia, and fatal aspiration pneumonia.
  • Pyloric Pill Propulsion: The mechanical turbulence of lavage fluids frequently pushes intact tablets through the pyloric sphincter into the duodenum, accelerating systemic drug absorption rather than removing it.
  • Lack of Proven Efficacy: Randomized clinical trials demonstrate no improvement in morbidity, ICU length of stay, or mortality compared to supportive care or charcoal alone.
• Current Stance: Routine gastric lavage is obsolete. It should only be contemplated in extraordinary circumstances where a patient has ingested a potentially lethal dose of a non-charcoal-adsorbing xenobiotic within 60 minutes, has an intact or intubated airway, and possesses no other antidotal recourse.

3. Cathartics: The Dangers of Overuse

Cathartics—such as sorbitol (70%) and magnesium citrate—were historically co-administered with activated charcoal to accelerate gastrointestinal transit and theoretically diminish toxin reabsorption.

• Monotherapy Ban: Cathartics have zero efficacy when used alone and must never be administered without activated charcoal.
• Single vs. Multiple Dosing: While a single dose of sorbitol combined with the first dose of activated charcoal is acceptable, repeated doses of cathartics are strictly contraindicated.
• Pathophysiological Complications of Repeat Dosing: Repeated osmotic cathartic administration causes massive intraluminal fluid shifts, precipitating severe hyperosmolar dehydration, profound hypernatremia, hypermagnesemia (with magnesium-containing salts), hypotension, and hypovolemic shock, particularly in young pediatric patients.

---

Comparative Matrix of Decontamination Modalities

---

Poison Center Case Scenario: The Sustained-Release Cardiotoxin Ingestion

A 42-year-old male is brought to the emergency department by EMS after ingesting thirty 240 mg tablets of sustained-release verapamil (total dose: 7.2 g) approximately 2.5 hours prior to arrival in a deliberate self-harm gesture. On arrival, the patient is awake, alert, and fully oriented (GCS 15). Vital signs are: blood pressure 114/72 mmHg, heart rate 68 beats/min (sinus rhythm on telemetry), respiratory rate 16 breaths/min, and oxygen saturation 98% on room air. The emergency physician contacts the Poison Center requesting advice on administering syrup of ipecac and gastric lavage.

Specialist in Poison Information Interventions

1. Reject Obsolete and Harmful Modalities: The CSPI immediately advises the physician against administering syrup of ipecac or performing gastric lavage. Ipecac carries high risks of intractable emesis and aspiration as the patient becomes obtunded, while gastric lavage is dangerous, ineffective at 2.5 hours, and risks pushing intact sustained-release tablets through the pylorus into the small intestine.
2. Decontamination Strategy Selection: Because this is a massive ingestion of a sustained-release cardiotoxic formulation with severe anticipated delayed lethality, the CSPI recommends:
   • Immediate Single-Dose Activated Charcoal (50 g orally) to adsorb any dissolved drug currently residing in the stomach.
   • Initiation of Whole Bowel Irrigation (WBI) using PEG-ELS (GoLYTELY) via a nasogastric tube at a rate of 1,500 to 2,000 mL/hr.
3. Proactive Airway and Antiemetic Safeguards: The CSPI instructs the team to administer ondansetron 8 mg IV before starting WBI to prevent nausea and emesis. The team is cautioned that verapamil SR causes delayed, precipitous hemodynamic collapse and central nervous system depression. If the patient's sensorium deteriorates or GCS drops below 14 during WBI, the infusion must be stopped immediately until the patient is electively intubated with an endotracheal tube to prevent catastrophic aspiration of PEG-ELS.
4. Procedural Endpoint: WBI must continue until the rectal effluent is completely clear and free of suspended pill fragments, typically requiring 4 to 8 hours of continuous lavage.